Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy

NCT00932282 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Peanut Hypersensitivity

Interventions

DRUG: Peanut Oral Immunotherapy
DRUG: Omalizumab

Sponsor

University of North Carolina, Chapel Hill

Collaborators

[object Object]